NATiV3

Don't let NASH be your silent partner.

The NATiV3 Study is now enrolling.

NASH (non-alcoholic steatohepatitis) is the result of fat buildup and inflammation in the liver, which can cause serious health hazards. If you have been diagnosed with NASH or liver fibrosis, you may be eligible to participate in a clinical study evaluating an investigational treatment.

To see if the NATiV3 Study is right for you, please contact us.

Location: MNGI Digestive Health, Northeast Minneapolis Clinic

Physician Investigator: Dr. Hanouneh

Study Coordinator: Naomi Mugarura

 

MONARCH

The MONARCH Study is now enrolling.

MAFLD (metabolic dysfunction - associated fatty liver disease) defines a range of conditions characterized by an increased amount of fat in the liver. MAFLD can develop into metabolic dysfunction - associated steatohepatitis (MASH), which is characterized by inflammation and fibrosis. If you have been diagnosed with MAFLD, MASH or liver fibrosis you may be eligible to participate in a clinical study evaluating an investigational treatment.

To see if the MONARCH Study is right for you, please contact us below.

Location: MNGI Digestive Health, Northeast Minneapolis Clinic

Physician Investigator: Dr. Hanouneh

Study Coordinator: Naomi Mugarura

ATTENTION: This form is for information only and does not guarantee participation in any study. This form is also not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Those inquiries should be sent through the Patient Portal or you can contact us at (612) 871-1145. Web form submissions are monitored Monday through Friday during regular business hours. In the event of a medical emergency, please dial 911.

CAPTCHA
14 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.